首页> 中文期刊> 《生殖与发育医学:英文版》 >Potential Application of Anti-Müllerian Hormone in Polycystic Ovary Syndrome According to Chinese Classification Criteria:A Retrospective Analysis

Potential Application of Anti-Müllerian Hormone in Polycystic Ovary Syndrome According to Chinese Classification Criteria:A Retrospective Analysis

         

摘要

Objective:Anti-Müllerian hormone(AMH)expression is elevated in patients with polycystic ovary syndrome(PCOS),however,its clinical significance is not clear.Owing to the strong correlation between AMH and polycystic ovarian morphology(PCOM),some studies believe that AMH alone can be used to diagnose PCOS.The aim of this study was to explore whether AMH can be used to diagnose PCOS and to differentiate the various PCOS subtypes.Methods:This was a retrospective study of 503 patients with PCOS.Patients were divided into eight subtypes based on the presence/absence of hyperandrogenemia(HA),insulin resistance(IR),or obesity(OB).The expression characteristics of AMH in each subtype were analyzed.Due to the small number of patients with subtypes 7 and 8,only patients with subtypes 1-6 were included in the analysis.Results:AMH showed a good positive correlation with PCOM(P=0.000)and negative correlations with OB(P=0.000)and IR(P=0.003).The free testosterone index showed no correlation with AMH(P=0.803).The percentages of patients with each subtype(excluding subtypes 7-8)and their respective AMH levels were as follows:Type 1(HA+NIR+OB)4.77% and 9.12 ng/mL;Type 2(HA+IR+NOB)20.68% and 10.34 ng/mL;Type 3(HA+NIR+NOB)23.66% and 9.47 ng/mL;Type 4(HA+IR+OB)30.82% and 8.32 ng/mL;Type 5(NHA+NIR+NOB)11.73% and 10.0 ng/mL;and Type 6(NHA+IR+NOB)6.16% and 9.76 ng/mL.The diagnostic rates of AMH(>8.09 ng/mL)and ultrasound for PCOM were 60.10% and 85.60% ,respectively,suggesting that AMH did not completely predict PCOM.Conclusions:High AMH levels can be used to evaluate the incidence trend of PCOS.However,due to clinical heterogeneity,accurately evaluating the severity of PCOS and identifying the subtype of PCOS in Chinese patients are difficult.Individualized treatment should be administered based on accurate clinical subtypes and other clinical characteristics.

著录项

  • 来源
    《生殖与发育医学:英文版》 |2020年第4期|P.228-232|共5页
  • 作者单位

    Department of Gynecology Changsha Maternal and Child Health Hospital Changsha 410007 ChinaDepartment of Gynecology Obstetrics and Gynecology Hospital of Fudan University Shanghai 200090 China;

    Department of Gynecology Obstetrics and Gynecology Hospital of Fudan University Shanghai 200090 ChinaShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases Shanghai 200011 China;

    Department of Gynecology Obstetrics and Gynecology Hospital of Fudan University Shanghai 200090 ChinaLaboratory for Reproductive Immunology Hospital and Institute of Obstetrics and Gynecology Shanghai Medical School Fudan University Shanghai 200011 China;

    Department of Gynecology Obstetrics and Gynecology Hospital of Fudan University Shanghai 200090 ChinaShanghai Key Laboratory of Female Reproductive Endocrine Related Diseases Shanghai 200011 China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 妇产科学;
  • 关键词

    Anti-Müllerian Hormone; Application Value; Polycystic Ovary Syndrome; Subtype;

    机译:抗Müllerian激素;应用价值;多囊卵巢综合征;亚型;
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号